

REMARKS

The amendments to the claims were previously submitted as a Preliminary Amendment to address formal matters. This includes the insertion of a reference to pharmaceutically acceptable salts into each claim that did not explicitly refer to salts, the insertion of missing conjunctions and punctuation, and the correction of spelling and grammatical errors. Pharmaceutically acceptable salts are already included in the preambles to Claims 1 and 2 and elsewhere in the application and claims, so that the insertion into the dependent claims is well supported. The missing conjunctions and punctuations and spelling and grammatical errors are obvious errors. Subject matter in Claim 11 was deleted which is not generally included in claims.

Claims 30-36 were amended in the Notice of Allowability by the Examiner in an Examiner's amendment that was approved in April, 2007. The amendment removed the gridlines from the tables and added punctuation and conjunctions, so that the claims were written in sentence form. These claims are not changed in this amendment.


As the claims were still pending when the Preliminary Amendment was sent, and a first office action had not been issued at that time, these amendments should have been entered when they were submitted in August. In a telephone conversation on October 1, Examiner Solola agreed that they should be entered now. Examiner Solola also reviewed the two publications that were sent in an Information Disclosure Statement on August 17 in response to the telephone inquiry.

Case No. 21036YP
Page - 22 -

The applicants' attorney is grateful to Examiner Solola for promptly addressing these matters in response to his telephone inquiry about the Notice of Allowance.

Entry of the amendment is respectfully requested.

Respectfully submitted,

By: 
James L. McGinnis
Reg. No. 34,387
Attorney for Applicants

Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-0641

Date: October 5, 2007